Malaria is a major cause of anaemia in tropical areas. Malaria infection causes haemolysis
of infected and uninfected erythrocytes and bone marrow dyserythropoiesis which …

Infections with Plasmodium falciparum and Plasmodium vivax cause over 600,000 deaths
each year, concentrated in Africa and in young children, but much of the world's population …

Malaria is the tropical disease most commonly imported into the UK, with 1300–1800 cases
reported each year, and 2–11 deaths. 2. Approximately three quarters of reported malaria …

Background: Artesunate (AS) is the WHO first-line treatment of severe malaria in endemic
countries, in adults and children. However, despite solid evidence that AS is safe and more …

Though morbidity and mortality due to malaria have declined in the last 15 years, emerging
resistance to first-line artemisinin-based antimalarials, absence of efficacious vaccines and …

New amide conjugates of hydroxycinnamic acids (HCAs) and the known antineoplastic 5, 11-
dimethyl-5 H-indolo [2, 3-b] quinoline (DiMIQ), an analog of the natural alkaloid …

Artesunate, the recommended drug for severe malaria, rapidly clears the malaria parasite
from infected patients but frequently induces anemia—called post-artesunate delayed …

Artemether, an artemisinin derivative, is used in the management of life-threatening severe
malaria. This study aimed to develop an intravenous dosage form of artemether using …

Introduction: Malaria in pregnancy and postpartum cause maternal mortality and adverse
fetal outcomes. Efficacious and safe antimalarials are needed to treat and prevent such …

Artesunate has replaced quinine as the recommended first-line treatment of severe malaria
as it clears parasites faster and lowers mortality. After artesunate's introduction, however …